Drop‐out Objective · Adults with mental disorders in low‐ and middle‐income countries
Metformin showed no clear difference in drop‐outs (12 to 14 weeks) compared with placebo (moderate certainty).
1 finding from 1 review
Fasting blood glucose (mg/dL) · Adults with mental disorders in low‐ and middle‐income countries
2 findings from 1 review
Body‐mass index (BMI) · Adults with mental disorders in low‐ and middle‐income countries
1 finding from 1 review
Dropout · opiate‐dependent pregnant women
Methadone showed no clear difference in dropout rate compared with buprenorphine (moderate certainty).
1 finding from 1 review
Birthweight (g) · opiate‐dependent pregnant women
1 finding from 1 review
APGAR score (APGAR score ) · opiate‐dependent pregnant women
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events for the mother · opiate‐dependent pregnant women
1 finding from 1 review
Serious adverse events for the child · opiate‐dependent pregnant women
1 finding from 1 review
Use of Primary Substance · opiate‐dependent pregnant women
Methadone showed no clear difference in use of primary substance compared with buprenorphine (low certainty).
1 finding from 1 review
Birthweight (g) · opiate‐dependent pregnant women
1 finding from 1 review
APGAR scoreScale from: 0 to 10 · opiate‐dependent pregnant women
1 finding from 1 review
Number treated for NAS · opiate‐dependent pregnant women
Methadone showed no clear difference in number treated for NAS compared with buprenorphine (low certainty).
1 finding from 1 review
Proportion of mothers with serious adverse events ( · opiate‐dependent pregnant women
Methadone showed no clear difference in serious adverse events for the mother compared with buprenorphine (low certainty).
1 finding from 1 review
Serious adverse events for the child · opiate‐dependent pregnant women
Methadone showed no clear difference in serious adverse events for the child compared with buprenorphine (low certainty).
1 finding from 1 review
Unacceptability of treatment (dropouts/exclusions during the trial) · opiate‐dependent pregnant women
1 finding from 1 review
Use of substance · opiate‐dependent pregnant women
Methadone showed no clear difference in use of substance compared with oral slow‐release morphine (low certainty).
1 finding from 1 review
All‐cause mortality · people at increased risk for developing type 2 diabetes
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Thiazolidinediones Diagnostic criteria: 2 trials applied the WHO 1999 criteria (FPG ≥ 7.0 mmol/L and/or a 2‐hour glucose ≥ 11.1 mmol/L after a 75 g OGTT) (Jin 2009; Zeng 2013). No medical association recommended the cut‐off points applied in Maji ... · people at increased risk for developing type 2 diabetes
Summary of findings table for metformin showed no clear difference in thiazolidinediones Diagnostic criteria: 2 trials applied the WHO… compared with diet and exercise or another antidiabetic drug (low certainty).
1 finding from 1 review
Intensive diet plus exercise · people at increased risk for developing type 2 diabetes
4 findings from 1 review
Show 1 more finding
Acarbose · people at increased risk for developing type 2 diabetes
3 findings from 1 review